Decibel Therapeutics is developing regenerative and gene therapy strategies to restore hearing and balance. Using their proprietary platform that integrates single-cell genomics and bioinformatics, Decibel is developing precision gene therapy technologies. These will be used to selectively replace genes for the treatment of congenital, monogenic hearing loss. They are also working to restore hair cell functionality for the treatment of acquired hearing and balance disorders. Ultimately, Decibel Therapeutics is creating a world of connection for people with hearing and balance disorders. 

<p>Decibel Therapeutics is developing regenerative and gene therapy strategies to restore hearing and balance. Using their proprietary platform that integrates single-cell genomics and bioinformatics, Decibel is developing precision gene therapy technologies. These will be used to selectively replace genes for the treatment of congenital, monogenic hearing loss. They are also working to restore hair cell functionality for the treatment of acquired hearing and balance disorders.</p>
<p>Ultimately, Decibel Therapeutics is creating a world of connection for people with hearing and balance disorders. </p>


Decibel Therapeutics

 Theo Wiley on LinkedIn: Pioneering gene therapy restores UK girl's hearing 

Decibel receives CTA clearance in UK for DB-OTO for otoferlin-related hearing loss - BioWorld Online

 Autodesk, EMC, Project 11 Join Influx Program on June 22 

Decibel to advance DB-OTO into clinic for otoferlin-related hearing loss - BioWorld Online

Decibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology - Business Wire

 David McAlpine GAICD on LinkedIn: UK toddler has hearing restored in world first gene therapy trial 

Decibel Therapeutics Appoints Healthcare Industry Veteran Christine A. Poon to its Board of Directors - Business Wire

Decibel receives AEMPS clearance to start congenital hearing loss therapy trial - Clinical Trials Arena

Regeneron ups genetic medicine investment with Decibel buyout - BioPharma Dive

Decibel CEO steps down as company pares workforce - BioPharma Dive

 Regeneron, Intellia target neurological diseases in expanded ... 

Regeneron Pharmaceuticals to Acquire Decibel Therapeutics - Pharmaceutical Technology Magazine

Chutes & Ladders—Chimerix CEO replaced by a trio of officers - Fierce Biotech

Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal - InvestorPlace

 Procrastinator’s Special Ends Today for INFLUX Tomorrow Afternoon 

 Decibel Therapeutics, Inc. (NASDAQ:DBTX) surges 80 ... 

The 'little protein factory' that could: Regeneron gene therapy restores hearing in 2 children - Fierce Biotech

 Hearing loss drug developer Decibel rounds up $55M in series C 

 StockWatch: Regeneron's All Ears for Hearing Loss Drug Developer 

Decibel Therapeutics announces study on noise-related inner ear damage - Drug Discovery & Development

 Decibel Therapeutics Closes $55 Million Series C to Treat Hearing Loss 

 Gene Therapy Racks up Success in Rare Genetic Hearing Disorder 

Decibel Therapeutics Announces Results of DB-020 Clinical Trial - TechTarget

Volume turns up on Decibel as hearing loss therapy protects patients in early-stage trial - FiercePharma

Third Rock Ventures Launches Decibel Therapeutics with ...

Decibel scores $82M to push hearing loss gene therapy ...

 Advancements in Sensorineural Hearing Loss Clinical Trial Pipeline as 20+ Companies Pave the Way for Future Solutions | DelveInsight 

 Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit 

 Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U.S. Food and Drug Administration 

Decibel Therapeutics submits IND application for hearing loss gene therapy candidate - Drug Target Review

 ‘Very nervous’: After Trump victory, concerns about Affordable Care Act’s future weigh on some in health care sector 

 Bio Roundup: Migraine Data, Cancer Drug Combos, Azar Hearing & More 

 Decibel Therapeutics Appoints Jeff Jonas, M.D., CEO of SAGE Therapeutics, to its Board of Directors 

Laurence Reid returns to biotech as he takes up Decibel CEO role - Fierce Biotech

Hearing Experts Launch Decibel Therapeutics for Drug Discovery - The Hearing Review

Decibel Therapeutics Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance - Business Wire

Laurence Reid returns to biotech as he takes up Decibel ...

Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration - Fierce Biotech

 Laurence Reid returns to biotech as he takes up Decibel CEO role 

Decibel adds first clinical candidate with Oricula license deal

 Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors 

Decibel Therapeutics Receives FDA Clearance of IND - GlobeNewswire

Pepper chemical piplartine can prevent hearing loss from powerful antibiotics - Fierce Biotech

 Decibel scores $82M to push hearing loss gene therapy into the clinic 

 Decibel signs unique partnership deal with Regeneron for hearing programs 

 Decibel Therapeutics, Strategic Education See Activist Action 

Decibel Therapeutics Announces Approval of Clinical Trial - GlobeNewswire

Otoferlin-Related Hearing Loss Gene Therapy DB-OTO Cleared for Clinical Trial Expansion to Spain - CGTLive™

In a pivot, Decibel Therapeutics loses its founding CEO — and some of its discovery programs - STAT

 Hearing disorder biotech Decibel Therapeutics files for a $75 million IPO 

​$52M says it’s possible to make drugs to slow or even cure hearing loss - The Business Journals

Regeneron Pharmaceuticals to Acquire Decibel Therapeutics - BioPharm International

Atsena Therapeutics Expands Leadership Team with - GlobeNewswire

 Decibel Hauls in $55M to Bring Multiple Hearing Drugs to the Clinic 

 Decibel Therapeutics Stock Soars on Acquisition Deal - The Details 

 Regeneron To Acquire Decibel Therapeutics 

Third Rock, Tango decamp to Boston's Fenway neighborhood - Fierce Biotech

Regeneron and Decibel Therapeutics Announce Strategic Collaboration - The Hearing Review

 Local facilities invest in tick-borne illness research, testing as ... 

 Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from S&P TMI Index 

Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program - Business Wire

Lilly spies value in biotech bear market, snapping up hearing loss gene therapy player Akouos for $487M - Fierce Biotech

StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer - Genetic Engineering & Biotechnology News

Decibel signs unique partnership deal with Regeneron for hearing programs - Fierce Biotech

Lessons Learned: This is why one person turned down a faculty position for a startup - STAT

Regeneron Gene Therapy Restores Hearing in Infant With Genetic Form of Deafness, Data at ASGCT Show - Precision Medicine Online

Decibel hires new CMO ahead of proof-of-concept hearing ...

Regeneron adds Decibel to gene therapy playlist in $109 ...

 Regeneron to acquire Decibel Therapeutics for $4.00 per share plus CVR 

 Decibel hires new CMO ahead of proof-of-concept hearing loss studies 

 Decibel Therapeutics (DBTX) Stock: Why It Surged 18.3% 

Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update - GlobeNewswire

Hearing Aid: Decibel Therapeutics CEO Laurence Reid Talks to Close to the Edge - Genetic Engineering & Biotechnology News

Regeneron To Acquire Decibel Therapeutics - Contract Pharma

Decibel Therapeutics Announces Leadership Transition - Business Wire

Decibel Therapeutics taps 4G Clinical for RTSM support

Regeneron to acquire Decibel Therapeutics in deal worth up to $213m - PMLiVE

Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting - Yahoo Finance

 Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss Associated with Cisplatin Chemotherapy 

Regeneron extends research agreement with Decibel Therapeutics - The Science Board

Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors - citybiz

 Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus 

Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals - Investopedia

Regeneron to buy gene therapy biotech Decibel Therapeutics in small $109M deal - Endpoints News

GV (Google Ventures) Invests in Decibel Therapeutics - The Hearing Review

Regeneron to Acquire Decibel Therapeutics to Boost Hearing Loss Therapy Programs - The Hearing Review

Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary - GlobeNewswire

 6 Startups Working on How to Fix Hearing Loss 

Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update - GlobeNewswire

 Decibel Therapeutics to Present at the Association for Research in Otolaryngology (ARO) Conference 

Regeneron Buys Decibel’s Hearing Loss Gene Therapies in $109M Deal - BioSpace

Third Rock Ventures and GlaxoSmithKline’s SR One Launch Decibel Therapeutics With $52 Million, Expect to Hire 50-60 By Year End - BioSpace

Regeneron to Acquire Decibel Therapeutics - Contract Pharma

 Decibel Therapeutics Presents at 2018 Annual Association for Research in Otolaryngology (ARO) Meeting 

Decibel signs unique partnership deal with Regeneron for ...

 Regeneron Adds Hearing Loss Gene Therapy Program Via Decibel Therapeutics Acquisition 

Google backs Decibel Therapeutics in big data hearing loss play - Drug Delivery Business News

Regeneron’s Gene Therapy Improves Auditory Responses in Children with Genetic Hearing Loss - The Hearing Review

 Decibel Therapeutics raises $82M as Laurence Reid looks to steer gene therapy pivot 

 CRISPR Could Soon Charge into Hearing Loss Drug Race, New Study Suggests 

Decibel Therapeutics

Business:

Drug notes:

About: